Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience
Abstract Background Despite all the scientific progress that has been made on understanding the disease, prognosis for patients with relapsed and refractory Hodgkin's lymphoma remains poor and the treatment is palliative in the majority of the cases. Thus, the aim of this study was to present the results on the compassionate use of everolimus in a group of patients who were monitored at nine different centers in Brazil. Methods A 10-mg oral dose of everolimus was given to each patient daily. Response time was evaluated from the beginning of medication use until loss of response, toxicity or medical decision to cease treatment. Results Thirty-three patients were evaluated. The median age at the beginning of medication administration was 29 years. Patients had received a median of five prior therapies. Overall response rate was 45.4%, with 13 patients achieving partial response, two achieved clinical response, 14 remained with stable disease, two had disease progression, and two were not evaluated. Patients received a median of 14 cycles. Progression-free survival was nine months, and overall survival was estimated to be 36 months. Three patients used the medication for more than four years. The most frequently reported adverse events were thrombocytopenia and hypercholesterolemia. Three patients had pulmonary toxicity. Grade III and IV adverse events occurred in 39% of the patients. Conclusion Everolimus was found to provide a response in a group of patients with refractory or relapsed Hodgkin's lymphoma who had adequate tolerability to the drug.
Main Authors: | Rocha,Talita Máira Bueno da Silveira da, Fortier,Sergio Costa, Fischer,Thais Rodrigues da Cunha, Perini,Guilherme Fleury, Gaiolla,Rafael Dezen, Fogliatto,Laura, Delamain,Marcia Torresan, Costa,Andressa Fragoso da, Castro,Nelson Siqueira de, Barretos,Wolney Gois, Souza,Cármino Antonio de, Buccheri,Valéria, Chiattone,Carlos Sérgio |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
2017
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842017000300216 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
New agents in relapsed/refractory Hodgkin's lymphoma
by: Biasoli,Irene, et al.
Published: (2017) -
Hodgkin's lymphoma in developing countries: can we go further?
by: Gaiolla,Rafael Dezen
Published: (2017) -
Fluorodeoxyglucose-positron emission tomography staging can replace bone marrow biopsy in Hodgkin's lymphoma. Results from Brazilian Hodgkin's Lymphoma Study Group
by: Cerci,Juliano Júlio, et al.
Published: (2018) -
Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients
by: Delamain,Marcia Torresan, et al.
Published: (2016) -
Evaluation correlates C-reactive protein with advanced stage Hodgkin's lymphoma and response to treatment in a tertiary university hospital in Brazil
by: Rocha,Talita Máira Bueno da Silveira da, et al.
Published: (2015)